Comparative Pharmacology
Head-to-head clinical analysis: DILACOR XR versus ISRADIPINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILACOR XR versus ISRADIPINE.
DILACOR XR vs ISRADIPINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Diltiazem inhibits calcium ion influx across cardiac and vascular smooth muscle cells, resulting in dilation of coronary and systemic arteries, decreased myocardial contractility, and reduced sinoatrial and atrioventricular conduction velocity.
Isradipine is a dihydropyridine calcium channel blocker that inhibits the influx of extracellular calcium ions into vascular smooth muscle and myocardial cells via L-type calcium channels, leading to vasodilation and reduced peripheral vascular resistance, with minimal negative inotropic effect.
180 to 240 mg orally once daily, administered on an empty stomach; maximum dose 480 mg once daily.
2.5-10 mg orally twice daily. Initial dose: 2.5 mg twice daily, titrate to 5-10 mg twice daily as needed.
None Documented
None Documented
Clinical Note
moderateIsradipine + Etacrynic acid
"The risk or severity of adverse effects can be increased when Isradipine is combined with Etacrynic acid."
Clinical Note
moderateIsradipine + Furosemide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Furosemide."
Clinical Note
moderateIsradipine + Bumetanide
"The risk or severity of adverse effects can be increased when Isradipine is combined with Bumetanide."
Clinical Note
moderateIsradipine + Travoprost
Terminal half-life: 6-12 hours (prolonged in elderly, hepatic impairment, or with CYP3A4 inhibitors)
Terminal elimination half-life 8 hours (range 6-12 hours); clinical context: supports twice-daily dosing, requires dose adjustment in hepatic impairment.
Renal (70% as metabolites, 3-4% as unchanged drug); biliary/fecal (25-30%)
Renal: 65% (as metabolites, <1% unchanged); Fecal: 35% (biliary elimination); total clearance 1.4 L/min.
Category C
Category C
Calcium Channel Blocker
Calcium Channel Blocker
"Isradipine may increase the hypotensive activities of Travoprost."